Indoximod

• Description :

  Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer[1][2].

• Product Name Alternative :

  1-Methyl-D-tryptophan; NLG-8189

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Indoleamine 2,3-Dioxygenase (IDO)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Indoximod.html

• Purity :

  99.85

• Solubility :

  0.5 M NaOH : 66.67 mg/mL (ultrasonic) |DMSO : 0.55 mg/mL (ultrasonic; warming) |H2O : 5 mg/mL (ultrasonic; adjust pH to 2 with HCl)

• Smiles :

  N[C@H](CC1=CN(C)C2=CC=CC=C12)C(O)=O

• Molecular Formula :

  C12H14N2O2

• Molecular Weight :

  218.26

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Hou DY, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophancorrelates with antitumor responses. Cancer Res. 2007 Jan 15;67 (2) :792-801.|[2]Metz R, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1 (9) :1460-1468.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  IDO

• CAS Number :

  [110117-83-4]